Deals channel feed – Endpoints News

Deals channel feed

AbbVie jumps into CD47 game, engineers $3B deal with ambitious Chinese player

5 years ago

Enthused by PhII autoimmune data, J&J kept Momenta waiting in the lead-up to $6.5B buyout

5 years ago

Weeks after launch, Alex Zhavoronkov's AI-inspired longevity spinout sells to Hong Kong-listed group

5 years ago

Casdin goes all-in on the SPAC game with $385M offering

5 years ago

Carlyle Group injects $260M into a leading cardio player in China, grabbing a seat at the deals table

5 years ago

Wheeling and dealing his way to a cancer drug pipeline, Gilead’s Dan O’Day crafts a rich, $805M deal to bag a preclinical I/O drug

5 years ago

A three-year experiment comes to an end, as Ionis reabsorbs Akcea for $500M

5 years ago

Sold for pennies, Unum gets one last shot at redemption

5 years ago

Unfazed by slow rollout, Nestlé buys out Aimmune and its peanut allergy med for $2.6B

5 years ago

Offers upped and upped again, CEO-to-CEO calls and perhaps a veiled walkout threat: Inside Sanofi CEO Paul Hudson's first big buyout

5 years ago

AbbVie and Harvard team up to find new drugs for the next new viruses

5 years ago

A Forbion-funded startup bought the rights to Amgen's CETP inhibitor, and is giving the cholesterol drug another go

5 years ago

Boehringer calls off €627M deal with GSK spinout, passing on schizophrenia drug option

5 years ago

Blackstone bankrolls supply chain player's deal spree with $275M

5 years ago

AbbVie options integrin-based compounds from Morphic, paving way for potential fibrosis treatments

5 years ago

Vir enlists Covid-19 antibody rival for cancer, infectious disease discovery work

5 years ago

Bristol Myers hunkers down at the deals table, executing a new I/O play in biotech buyout

5 years ago

Tony Coles takes second neuroscience startup public as Yumanity reverse merges

5 years ago

Which big biopharma player should gamble $34B on a ripe rare-disease M&A target? An action-hungry top analyst fills in the blanks

5 years ago

Takeda gets a $2.2B deal for its OTC unit as debt-relief drive nears its end

5 years ago

Is Takeda’s post-Shire sell-off approaching its final days?

5 years ago

Covid-19 roundup: Fauci, Collins intervene to stop FDA plasma authorization, citing weak data; Roche, Regeneron try to take antibodies global

5 years ago

J&J inks industry's latest bolt-on buyout with $6.5B deal to acquire Momenta, beefing up its autoimmune pipeline

5 years ago

Looking to expand beyond diabetes, Novo Nordisk enlists Evotec in CKD pact worth up to $179M per program

5 years ago

First page Previous page 86 87 888990 91 92 Next page Last page